Jeffrey Hassall ESA-SRB-AOTA 2019

Abstracts this author is presenting:

• Skeletal benefit/risk of long-term denosumab therapy: A virtual twin analysis of fractures prevented to skeletal safety events observed — ESA Posters - Clinical
• Subgroup analysis of the effect of denosumab compared with risedronate on percentage change in lumbar spine bone mineral density at 24 months in glucocorticoid-treated individuals — ESA Posters - Clinical